News

Pfizer bid to expand Talzenna use in prostate cancer questioned by FDA panel
Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...
Fierce Pharma6d
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...
Reuters8d
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...
BioPharma Dive5d
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
New York Post10d
Pfizer scientist claimed COVID vax results being delayed until after 2020 election ‘wasn’t a coincidence’: House GOP panel
WASHINGTON — The release of COVID-19 vaccine results after the 2020 election may have not been a “coincidence” — and could have been part of an effort by senior Pfizer executives to ...
WGAL12d
House GOP requests records from Pfizer in probe of COVID vaccine delay allegation
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...
WAPT12d
House GOP requests records from Pfizer in probe of COVID vaccine delay allegation
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...